GPC3 and hepatocellular carcinoma: Consistent with these findings, a potent GPC3-targeted antibody has been shown to induce G1 phase arrest and thus inhibit the proliferation of HCC cells in vitro and in vivo through interfering with the YAP-signaling pathway [95].